ORIX CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,188 JPY | +0.22% |
|
+2.48% | +20.03% |
| Apr. 15 | MC Healthcare, Inc. acquired FreeIll Co., Ltd. from ORIX Corporation. | CI |
| Apr. 04 | S&P Global Ratings Cuts Orix's Rating, Outlook Remains Stable | MT |
Strengths
- With a P/E ratio at 11.23 for the current year and 9.34 for next year, earnings multiples are highly attractive compared with competitors.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Consumer Lending
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +20.03% | 23.61B | B | ||
| -8.14% | 54.11B | C+ | ||
| -5.25% | 31.94B | C+ | ||
| +64.11% | 29.16B | - | - | |
| +16.94% | 18.17B | B | ||
| -6.99% | 11.64B | C+ | ||
| +21.92% | 11.25B | B- | ||
| -23.72% | 8.02B | - | ||
| +14.34% | 7.98B | C | ||
| +36.65% | 6.38B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 8591 Stock
- Ratings ORIX Corporation
